On March 28, 2012, Northstar Rx LLC won FDA approval of its ANDA for the combined oral contraceptive ELINEST (norgestrel and ethinyl estradiol), positioning the manufacturer to compete within a lucrative women's healthcare market. The approval of this brand-name alternative from a solid company like Northstar Rx could impact the competitive landscape, likely pressuring competitors to defend their market share against rising supply chain leverage.